Optimising TRIUMPH with 6·25 mg chlorthalidone
Lancet Glob Health
.
2020 Feb;8(2):e175.
doi: 10.1016/S2214-109X(19)30535-2.
Authors
Anil Pareek
1
,
C Venkata S Ram
2
,
Ravi T Mehta
3
,
Shruti Dharmadhikari
3
Affiliations
1
Ipca Laboratories, Mumbai 400067, India. Electronic address: anil.pareek@ipca.com.
2
Apollo Medical College and Hospitals, Hyderabad, India.
3
Ipca Laboratories, Mumbai, India.
PMID:
31981550
DOI:
10.1016/S2214-109X(19)30535-2
No abstract available
Publication types
Letter
Comment
MeSH terms
Antihypertensive Agents
Chlorthalidone*
Cost-Benefit Analysis
Humans
Hypertension*
Sri Lanka
Substances
Antihypertensive Agents
Chlorthalidone